The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
As per 10th edition of International Diabetes Federation (IDF) Atlas, 2021, India has 74.2 million people with diabetes between the age of 20-79 years
GlobalData predicts the average prices of dual chamber pacemakers in both India and China are expected to reduce at an average CAGR of -3.42% from 2022 to 2025.
LHWRF will work with the State’s Department of Health and Family Welfare for strengthening the healthcare system and addressing the prevalence of CVD and COPD for better outcomes
There are certain foods can influence blood pressure, triglycerides, cholesterol levels and inflammation, all of which are risk factors for heart disease.
Patients with moderate or elevated risk in the test should immediately consult a cardiologist for further diagnosis and workup
The #Heart2HeartChallengeIndia campaign is very simple – you have to climb 60 steps in a minute, make a video of it, share it on your social media, tag 5 people, inviting them to take this challenge to check their heart health
The Allurion Program is suited for people who are unable to achieve their weight-loss goals by dieting alone or for those who do not want to, or cannot, undergo invasive surgery or endoscopy
Subscribe To Our Newsletter & Stay Updated
